Doina Ionescu, Managing Director and General Manager for Merck Healthcare UK and Ireland, has been elected to the Board of Directors for the Association of British Pharmaceutical Industry (ABPI).
Dr Ionescu has been elected to represent medium-sized companies on the ABPI Board of Directors and aims to further strengthen the relationship and UK innovation ecosystem between the pharmaceutical industry, patients, the NHS and the UK economy.
Among the areas that Doina has a particular passion for are personalised healthcare and shared decision making, supporting carers of patients and women in STEM (science, technology, engineering, maths). In 2021, Merck will be focusing on these three areas in addition to championing the views on medium-sized companies working in the pharmaceutical sector.
Doina began her career with Merck in 1998 working in R&D in Southampton. Since then she has held various senior positions within the company including in Corporate Business Development, Life Science and Healthcare. Before becoming the General Manager for Merck Healthcare UK & ROI she was the Global Head of Business Innovation.
Since joining Merck UK and ROI in May 2020 as General Manager, Doina has successfully maintained the established portfolio of Merck therapies, delivering profitable growth during the pandemic and empowering teams to launch treatments for fertility and bladder cancer, entirely virtually. She has also championed the development of digital capabilities including piloting new concepts around artificial intelligence and understanding of customer needs. Driving innovation through a culture of diversity, inclusion and agility will continue to be a key priority for her.
Commenting on her election, Dr Ionescu said: “I feel privileged and delighted to have been elected onto the ABPI Board of Directors. If there was ever any doubt, last year has demonstrated the paramount importance of a strong, trusting and collaborative relationship between our industry and the wider health system.”
“I look forward to working with Richard Torbett (Chief Executive, ABPI), Ben Osborn (President, ABPI and MD, Pfizer) and Pinder Sahota (Vice President, ABPI and GM,Novo Nordisk) to ensure that the priorities of mid-sized ABPI members are addressed at the ABPI Board level, informing our shared industry vision for UK life sciences,” she added.